Newsroom

Recent news, statements, and resources

Newsroom

Recent news, statements, and resources

Welcome to The Leukemia & Lymphoma Society Newsroom

Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.

An image with the word "news" on tablets and a laptop

The Leukemia & Lymphoma Society Denounces Federal Actions that Threaten Cancer Patients

February 11, 2025

LLS CEO, staff and supporters ring Nasdaq opening bell to mark progress for blood cancer patients

The Leukemia & Lymphoma Society Rings Nasdaq Bell to Mark 75 Years of Progress and Announce its Bold Goal for the Future

January 30, 2025

Stacking Up Hope: 75 Participating IHOP Locations Unite with The Leukemia & Lymphoma Society to Support Blood Cancer Patients

January 30, 2025

An image depicting tablets and laptops with text that reads news

In the Face of Uncertainty in Washington, The Leukemia & Lymphoma Society Stands with Patients

January 30, 2025

Image of text that reads "Breaking News" over blood cancer cells.

Newly FDA-approved Treatment Enhances Survival for Children and Adults with 2 Blood Cancer Types

January 28, 2025

Image of text that reads "Breaking News" over lymphoma cells.

First 2025 New Blood Cancer Drug Approval Adds Years of Life for People Living with Mantle Cell Lymphoma

January 17, 2025

An image depicting tablets and laptops with text that reads news

Resources for Blood Cancer Patients and Families Affected by the California Wildfires

January 17, 2025

An image depicting tablets and laptops with text that reads news

The Leukemia & Lymphoma Society Names Lore Gruenbaum, Ph.D., New Chief Scientific Officer

January 14, 2025

Image of text that reads "Breaking News" over blood cancer cells.

FDA Approves New Drug to Treat a Serious Immune Condition that Can Affect Children with Blood Cancer

January 3, 2025

Media Requests

For all media-related inquiries and interview requests please email mediarelations@lls.org. An LLS representative will respond as soon as possible.